deferasirox has been researched along with cyclin d1 in 3 studies
Studies (deferasirox) | Trials (deferasirox) | Recent Studies (post-2010) (deferasirox) | Studies (cyclin d1) | Trials (cyclin d1) | Recent Studies (post-2010) (cyclin d1) |
---|---|---|---|---|---|
832 | 136 | 572 | 10,885 | 70 | 5,157 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Dreyling, M; Granot, G; Levi, I; Mor-Tzuntz, R; Nathan, I; Shpilberg, O; Vazana-Barad, L | 1 |
Ford, SJ; Jansson, PJ; Kalinowski, DS; Kovacevic, Z; Lovejoy, DB; Lui, GY; Obeidy, P; Richardson, DR; Sharp, DM; Tselepis, C | 1 |
Avigad, S; Granot, G; Lubin, I; Raanani, P; Samara, A; Shapira, S; Shpilberg, O | 1 |
3 other study(ies) available for deferasirox and cyclin d1
Article | Year |
---|---|
Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma.
Topics: Antineoplastic Agents; Apoptosis; Benzoates; Cell Cycle; Cell Line, Tumor; Cell Survival; Cyclin D1; Deferasirox; Gene Expression Regulation, Neoplastic; Humans; Iron; Iron Chelating Agents; Lymphoma, Mantle-Cell; Proteasome Endopeptidase Complex; Proteolysis; RNA, Messenger; Triazoles | 2013 |
The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.
Topics: Administration, Oral; Animals; Antigens, CD; Antineoplastic Agents; Apoptosis; Benzoates; Cell Cycle; Cell Line, Tumor; Copper; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Deferasirox; Female; Humans; Iron; Iron Chelating Agents; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Neuroectodermal Tumors, Primitive, Peripheral; Protein Serine-Threonine Kinases; Receptors, Transferrin; Small Cell Lung Carcinoma; Transplantation, Heterologous; Triazoles; Zinc | 2013 |
Deferasirox induces cyclin D1 degradation and apoptosis in mantle cell lymphoma in a reactive oxygen species- and GSK3β-dependent mechanism.
Topics: Apoptosis; Cell Line, Tumor; Cyclin D1; Deferasirox; Glycogen Synthase Kinase 3 beta; Humans; Iron Chelating Agents; Lymphoma, Mantle-Cell; Proteolysis; Reactive Oxygen Species; Tumor Cells, Cultured | 2021 |